Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis
- PMID: 1311022
- DOI: 10.1097/00005072-199201000-00010
Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis
Abstract
In order to evaluate the incidence and prognostic significance of gene amplification in primary brain neoplasms we measured the number of gene copies per cell of three oncogenes (epidermal growth factor receptor [EGFR] gene, N-myc, C-myc) and syntenic control genes in 40 specimens using quantitative DNA dot blots. We observed EGFR gene amplification in astrocytomas and anaplastic astrocytomas with approximately the same incidence as in glioblastoma multiforme (33%), although large amplifications were only seen in glioblastoma multiforme. Fourteen patients had a supratentorial glioblastoma multiforme; six had EGFR gene amplification and eight had either normal EGFR gene copy number or elevated EGFR copy number attributable to extra copies of chromosome 7. Patients with gene amplification had shorter survival than patients without gene amplification (p = 0.01). The observed difference in survival was not likely to be due to group differences in age, sex, treatment, or histopathology.
Similar articles
-
Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.J Neurosurg. 1994 Sep;81(3):427-36. doi: 10.3171/jns.1994.81.3.0427. J Neurosurg. 1994. PMID: 8057151
-
Two independent amplification events on chromosome 7 in glioma: amplification of the epidermal growth factor receptor gene and amplification of the oncogene MET.Anticancer Res. 1994 Mar-Apr;14(2A):577-9. Anticancer Res. 1994. PMID: 8017863
-
Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis.J Neurol. 1995 Oct;242(10):683-8. doi: 10.1007/BF00866920. J Neurol. 1995. PMID: 8568531
-
Amplified cellular oncogenes in neoplasms of the human central nervous system.Mutat Res. 1992 May;276(3):299-306. doi: 10.1016/0165-1110(92)90016-3. Mutat Res. 1992. PMID: 1374522 Review.
-
EGFR as a clinical marker in glioblastomas and other gliomas.Int J Biol Markers. 2018 Jan;33(1):22-32. doi: 10.5301/ijbm.5000301. Int J Biol Markers. 2018. PMID: 28885661 Review.
Cited by
-
Current clinical development of PI3K pathway inhibitors in glioblastoma.Neuro Oncol. 2012 Jul;14(7):819-29. doi: 10.1093/neuonc/nos117. Epub 2012 May 22. Neuro Oncol. 2012. PMID: 22619466 Free PMC article. Review.
-
Progress on molecular biomarkers and classification of malignant gliomas.Front Med. 2013 Jun;7(2):150-6. doi: 10.1007/s11684-013-0267-1. Epub 2013 May 17. Front Med. 2013. PMID: 23681890 Review.
-
CAIX Regulates GBM Motility and TAM Adhesion and Polarization through EGFR/STAT3 under Hypoxic Conditions.Int J Mol Sci. 2020 Aug 14;21(16):5838. doi: 10.3390/ijms21165838. Int J Mol Sci. 2020. PMID: 32823915 Free PMC article.
-
Immunohistochemical markers for prognosis of cerebral glioblastomas.J Neurooncol. 2002 Jul;58(3):217-36. doi: 10.1023/a:1016218117251. J Neurooncol. 2002. PMID: 12187957
-
Bcl-2 expression in higher-grade human glioma: a clinical and experimental study.J Neurooncol. 2000 Jul;48(3):207-16. doi: 10.1023/a:1006484801654. J Neurooncol. 2000. PMID: 11100818
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous